VivoSim Labs (VIVS) Stock Price

VivoSim Labs Price

NASDAQ·CLOSED
0.17
​
Market closed

Revenue at VivoSim Labs has contracted by 14.6% per year over the past 14 years to 131,000.00 USD. For VivoSim Labs, the net margin of -10,567.2% is down versus -763.2% a few years ago.

VivoSim Labs stock price

Access this data via the Eulerpool API

VivoSim Labs business model & stock analysis

Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in Solana Beach, California and currently employs 6 full-time employees. The company went IPO on 2013-08-02. The firm focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. The company is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Frequently asked questions about VivoSim Labs

7 analysts currently rate the VivoSim Labs stock: 0 recommend buying, 4 holding and 3 selling.

Converted at the current exchange rate, the VivoSim Labs share trades at 0.15 EUR (0.17 USD).

The VivoSim Labs share (VIVS) is listed on 4 stock exchanges, including: NASDAQ (ONVO), London (0R02.L), Frankfurt (4OR1.F), München (4OR1.MU).

The revenue of VivoSim Labs is 131,000.00 USD. This figure is based on current financial data and reflects the company's business performance.

The profit of VivoSim Labs is -13.84 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of VivoSim Labs is currently -0.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the VivoSim Labs stock.

The price-to-sales ratio (P/S) of VivoSim Labs is currently 3.36. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the VivoSim Labs stock.

The Eulerpool Quality Score for VivoSim Labs is 2/10.

The ISIN of VivoSim Labs is US68620A3023. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of VivoSim Labs is A2QA6Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of VivoSim Labs is VIVS. The ticker symbol is used to trade VivoSim Labs shares on the stock exchange.

Fair ValueTerminal
0.14 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
14,555.56 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website organovo.com
Currency
USD
Initial public offering
Aug 2, 2013
ISIN
US68620A3023
Cusip
68620A203
Sedol
BN2C1T0
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-0.02
P/S
P/Se
1.90
EV/EBIT
0.37
P/B Ratio
0.04
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
2,123.16 %
Last updated Oct 14, 2026, 12:56 PM

VivoSim Labs Peer Group

VivoSim Labs Ticker

FRANKFURT · 4OR1.FLONDON · 0R02.LMUNICH · 4OR1.MUNASDAQ · ONVO

All fundamentals and in-depth analysis of VivoSim Labs

Our stock analysis for VivoSim Labs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VivoSim Labs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.